Lack of a kinetic interaction between fluconazole and mexiletine

European Journal of Clinical Pharmacology

Volumn 50, Issue 1-2, 1996, Pages 129-131

  Ueno, K ^a   Yamaguchi, R ^a   Tanaka, K ^b   Sakaguchi, M ^c   Morishima, Y ^d   Yamauchi, K ^e   Iwai, A ^e  

^a National Sengokuso Hospital   (Japan)

^b Sirasagi Hospital   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KINDAI UNIVERSITY HOSPITAL   (Japan)

^e Department of Pharmacy   (Japan)

Author keywords

CYP1A2; Drug interaction; Fluconazole; Metabolism; Mexiletine

Indexed keywords

CYTOCHROME P450 ISOENZYME; FLUCONAZOLE; MEXILETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG INTERACTION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANTI-ARRHYTHMIA AGENTS; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUCONAZOLE; HALF-LIFE; HUMANS; MALE; MEXILETINE; OXIDOREDUCTASES;

EID: 0030011940     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050080     Document Type: Article

References (24)

1. Abolfathi Z, Pakdel H, Beaune P, Turgeon J (1995) CYP1A2 is the major involved the N-oxidation of mexiletine in man. Clin Pharmacol Ther 57:215 (Ninety-sixth annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Abstract)
2. Allaf EL, Carlier J, Dresse A (1986) Effect of age on the pharmacokinetics of mexiletine. Int J Pharm Res 4:303-307
3. Begg EJ, Chinwah PM, Webb C, Day RO, Wade DN (1982) Enhanced metabolism of mexiletine after phenytoin administration. Br J Clin Pharmacol 14:219-223
4. Bekett AH, Chidomere EC (1977) The distribution, metabolism and excretion of mexiletine in man. Postgrad Med 53 (Suppl 1): 60-66
5. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ (1991) Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 49: 420-425
6. Brown MW, Madonado AL, Meredith CG, Speeg KV (1985) Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther 37:290-297
7. Cannon RH, Anderson ML (1992) Fluconazole-nortriptyline drug interaction. Ann Pharmacother 26:1456-1457
8. Crussell-Poter LL, Rindone JP, K, Ueno, Ford MA, Jaskar DW (1993) Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 153:102-104
9. Hajek KK, Cook NI, Novak RL (1982) Mechanism of inhibition of microsomal drug metabolism by imidazole. J Pharmacol Exp Ther 223:97-104
10. Haselbarth V, Dovendon JE, Wolf M (1981) Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 29:729-736
11. Honig PK, Wortham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR (1993) The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in human. Clin Pharmacol Ther 630-636
12. Katz A, Buskila D, Sukenik S (1987) Oral mexiletine-theophylline interaction. Int J Cardiol 17:227-228
13. Kerr HD (1993) Potentiation of warfarin by fluconazole. Am J Med Sci 305:164-165
14. Konishi H, Morita K, Yamaji A (1994) Effect of fluconazole on theophylline disposition in humans. Eur J Clin Pharmacol 46:309-312
15. Lazar JD, Wilner KD (1990) Drug interactions with fluconazole. Rev Infect Dis 12:8327-333
16. Mastropaolo W, Holmes DR, Osborn MJ, Rooke J, Moyer TP (1984) Improved liquid-chromatographic determination of mexiletine, an antiarrhythmic drug, in plasm. Vlin Chem 30/2:319-322
17. Morita K, Konishi H, Shimakawa H (1992) Fluconazole: a potent inhibitor of cytochrome P450-dependent drug-metabolism in mice and humans in vivo. Comparative study with ketoconazole. Chem Pharm Bull 40:1247-1251
18. Pentikainen PJ, Koivula IH, Hiltnunen HA (1982) Effect of rifampicin treatment on the kinetics of mexiletine. Eur J Clin Pharmacol 23:201-206
19. Pringle T, Fox J, Mcneill A, Kinney CD, Liddle J, Harron DWG, Shanks RG (1986) Dose independent pharmacokinetics of mexoletone in healthy volunteers. Br J Clin Pharmac: 319-321
20. 1H nuclear magnetic resonance in the characterization of 1-methy-(2,6-xylyloxy) ethylamine metabolites. Drug Metab Dispos 1:506-515
21. Ueno K, Miyai K, Seki T, Kawaguchi Y (1990) Interaction between theophylline and mexiletine. DICP Ann Pharmacother 24:471-472
22. Ueno K, Miyai K, Kato M, Kawaguchi Y, Suzuki (1991) Mechanism of interaction between theophylline and mexiletine. DICP Ann Pharmacother 25:727-730
23. Woosley RL, Wang T, Stone W (1984) Pharmacology, electrophysiology and pharmacokinetics of mexiletine. Clin Pharmacol Ther 107:1058-1065
24. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for the microcomputer. J Pharmacobio Dyn 4:879-885